Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Techne, Akoya Biosciences Partner to Develop Automated Spatial Multiomics Workflow

NEW YORK ─ Bio-Techne and Akoya Biosciences on Wednesday announced a partnership to develop a single-cell, spatial multiomics workflow for the analysis of tissue samples.

Through the agreement, the partners intend to commercialize an automated, spatial multiomics workflow that can perform rapid, in situ analysis of multiple analytes at single-cell resolution and across whole slides, the firms said.

Minneapolis-based Bio-Techne and Marlborough, Massachusetts-based Akoya will also develop and comarket protocols to enable automated workflows for running Bio-Techne's RNAScope assays on Akoya's spatial phenotyping systems.

Financial and other terms of the agreement were not disclosed.

The partners said Akoya's PhenoCycler-Fusion System, due to launch this month, will run the firm's protein imaging assays and automate Bio-Techne's RNAScope HiPlex v2 assay for RNA imaging.

Combining the PhenoCycler-Fusion workflow with the RNAScope HiPlex v2 assay, part of Bio-Techne's Advanced Cell Diagnostics portfolio, has the potential to accelerate scientific understanding of complex diseases like cancer, the firms said.

Spatial multiomics approaches can also unlock new biomarker diagnostic signatures, enabling better stratification of patients and improving treatment outcomes, they noted, adding that the new, combined workflow complements Akoya's spatial transcriptomics capabilities, which are in development, and serves as a validation tool for deep spatial phenotyping applications.

The Scan

Rapid Test Studies

Researchers are examining why rapid tests may be less effective at detecting the Omicron variant and how to improve them, NPR says.

PLOS Papers on SARS-CoV-2 Diversity in Delaware, Metastatic Breast Cancer, Adiposity GWAS

In PLOS this week: genomic analysis of SARS-CoV-2 isolates from Delaware, gene expression and protein-protein interaction patterns in metastatic breast cancer, and more.

Omicron's Sewage Path

The New York Times writes that testing sewage is helping public health officials track Omicron.

IBM Sells Part of Watson Health

The Wall Street Journal reports IBM is selling part of its Watson Health business to an investment firm.